1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
COSMOS Pharmaceutical Corporation

COSMOS Pharmaceutical Corporation

3349.T
COSMOS Pharmaceutical CorporationJP flagTokyo Stock Exchange
6,650.00
JPY
+229.00
- -
527.06BMarket Cap

Total Valuation

COSMOS Pharmaceutical Corporation carries a market capitalization of 527.06B, placing it among publicly traded companies globally. Its enterprise value stands at 571.87B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap527.06B
Enterprise Value571.87B

Share Statistics

COSMOS Pharmaceutical Corporation currently has 79.26M shares outstanding.

Shares Outstanding79.26M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

COSMOS Pharmaceutical Corporation trades at a trailing price-to-earnings ratio of 45.49. The price-to-sales ratio is 1.20, and the price-to-book ratio stands at 2.45.

PE Ratio45.49
PS Ratio1.20
PB Ratio2.45
P/TBV Ratio2.41
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, COSMOS Pharmaceutical Corporation trades at an EV/EBITDA multiple of 36.51 and an EV/FCF ratio of 11,463.43. The EV/Sales ratio of 1.17 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 36.51 provides insight into valuation relative to core operating earnings.

EV / Sales1.17
EV / EBITDA36.51
EV / EBIT36.51
EV / FCF11,463.43

Financial Position

COSMOS Pharmaceutical Corporation maintains a current ratio of 0.70, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.54, indicating elevated leverage, while an interest coverage ratio of 244.75 demonstrates strong ability to service its debt obligations.

Current Ratio0.70
Quick Ratio0.18
Debt / Equity10.54
Debt / EBITDA1.64
Interest Coverage244.75

Financial Efficiency

COSMOS Pharmaceutical Corporation posts a return on equity of 5.66 and a return on invested capital of 4.74.

Return on Equity (ROE)5.66
Return on Assets (ROA)2.79
Return on Invested Capital (ROIC)4.74
Return on Capital Employed (ROCE)5.26
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover4.39

Taxes

Over the trailing twelve months, COSMOS Pharmaceutical Corporation has paid 3.64B in income taxes, reflecting an effective tax rate of 22.05.

Income Tax3.64B
Effective Tax Rate22.05

Stock Price Statistics

COSMOS Pharmaceutical Corporation's stock has declined approximately -30.78684% over the past 52 weeks. The 50-day moving average sits at 6,091.98, while the 200-day moving average is 7,018.52.

Beta (5Y)N/A
52-Week Price Change-30.78684%
50-Day Moving Average6,091.98
200-Day Moving Average7,018.52
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, COSMOS Pharmaceutical Corporation generated 488.56B in revenue and converted that into 12.87B in net income, yielding earnings per share of 162.33. EBITDA reached 15.66B, while operating income came in at 15.66B.

Revenue488.56B
Gross Profit95.37B
Operating Income15.66B
Pretax Income16.51B
Net Income12.87B
EBITDA15.66B
EBIT15.66B
Earnings Per Share (EPS)162.33

Balance Sheet

COSMOS Pharmaceutical Corporation holds 39.13B in cash and equivalents against 25.68B in total debt, resulting in a net debt position of -13.45B. Total book value stands at 238.51B, with working capital of -62.81B providing operational flexibility.

Cash & Cash Equivalents39.13B
Total Debt25.68B
Net Debt-13.45B
Equity (Book Value)238.51B
Book Value Per Share3,009.31
Working Capital-62.81B

Margins

COSMOS Pharmaceutical Corporation operates with a gross margin of 19.52, reflecting its pricing power and cost economics. The operating margin of 3.21 and net profit margin of 2.63 provide insight into operational efficiency.

Gross Margin19.52
Operating Margin3.21
Pretax Margin3.38
Profit Margin2.63
EBITDA Margin3.21

Stock Splits

COSMOS Pharmaceutical Corporation's most recent stock split took place on August 29, 2024 with a 1:2 split ratio.

Last Split Date8/29/2024
Split Ratio1:2

Scores

COSMOS Pharmaceutical Corporation posts an Altman Z-Score of 3.08, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.08